Adalimumab

Active ingredient description

Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC₅₀ of 0.1-0.2 nM).

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

L04AB04

Adalimumab

L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors

Discover more medicines within L04AB04

Medicines

Adalimumab is the active ingredient of these drugs:

AMGEVITA

Australia Austria Brazil Cyprus France

AMSPARITY

Austria Ireland Lithuania

CYLTEZO

Lithuania

HADLIMA

Australia

HALIMATOZ

Austria Lithuania

HEFIYA

Austria Ireland Lithuania

HUKYNDRA

Ireland

HULIO

Austria France Germany Ireland Lithuania

HUMIRA

Australia Austria Brazil Canada Cyprus

HYRIMOZ

Australia Austria Brazil Cyprus France

IDACIO

Australia Austria Brazil Cyprus France

IMRALDI

Austria Cyprus France Germany Ireland

KROMEYA

Lithuania

LIBMYRIS

Ireland

SOLYMBIC

Lithuania

XILBRILADA

Brazil

YUFLYMA

Germany Ireland Lithuania United Kingdom

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

HUMIRA 40mg/0.8ml Solution for injection in pre-filled syringe / pen